Clinical Trial Update: Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Sonrotoclax, Zanubrutinib, and a CD20 monoclonal antibody in untreated mantle cell lymphoma is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CD20 monoclonal antibody
• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: MCL | Phase 2 | Status: RECRUITING